Alnuctamab, a bivalent B-cell maturation antigen-targeting T cell engager for patients with relapsed or refractory multiple myeloma: results from a phase 1, first-in-human study
Alnuctamab 是一种靶向 B 细胞成熟抗原的二价 T 细胞衔接器,用于治疗复发或难治性多发性骨髓瘤患者:一项 1 期首次人体试验的结果
期刊:Leukemia
影响因子:13.4
doi:10.1038/s41375-025-02841-x
Bar, Noffar; Martin, Thomas; Hofmeister, Craig C; Mateos, Maria-Victoria; Hansson, Markus; Paris, Laura; Namburi, Swathi; Ribas, Paz; Santoro, Armando; Rodriguez-Otero, Paula; Creignou, Maria; Chen, Jinjie; Cao, Cong; Kiesel, Brian; Gaudy, Allison; Thompson, Ethan G; Shen, Ye; Zarif, Samah; Hsu, Kevin; Shelat, Suresh G; Burgess, Michael R; Godwin, Colin; Costa, Luciano J